Back to Search
Start Over
Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review.
- Source :
-
JAAD international [JAAD Int] 2023 Aug 31; Vol. 13, pp. 134-136. Date of Electronic Publication: 2023 Aug 31 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Competing Interests: Dr Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Allergan, Amgen, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Fresnius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Dr Mufti has been a speaker for AbbVie and Janssen. Author Sood has no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2666-3287
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- JAAD international
- Publication Type :
- Academic Journal
- Accession number :
- 37786789
- Full Text :
- https://doi.org/10.1016/j.jdin.2023.08.015